Skip to Main Content

++

INTRODUCTION

++

imiquimod (i-mi-kwi-mod)

Aldara

Classification

Therapeutic: antivirals, immune modifiers

Pharmacologic: immune response modifiers

++
Indications
++

External genital or perianal warts/condylomata (condyloma acuminatum). Typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp. Biopsy-confirmed, primary superficial basal cell carcinoma.

++
Action
++

May induce the formation of interferons that have antiproliferative and antiviral properties. Therapeutic Effects: Regression of external genital or perianal warts/condylomata, actinic keratoses, or basal cell carcinoma lesions.

++
Adverse Reactions/Side Effects
++

Local: irritation, pain, pruritus, burning, swelling, fungal infections (women).

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Assess skin lesions whenever possible to help determine if drug therapy is successful in controlling infection. Report any local irritation, pain, itching, swelling, or other skin reactions at the application site.

++
Interventions
++

  • Avoid contact with cutaneous lesions when treating patient.

  • Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection. Use universal precautions as indicated for specific patients.

++
Patient/Client-Related Instruction
++

  • Advise patient to apply medication as directed. Imiquimod should not be used more frequently or longer than prescribed.

  • For patients with actinic keratosis and basal cell carcinoma, advise patient to use sunscreens, wear protective clothing, and avoid prolonged sun exposure to prevent further skin damage from UV rays.

++
Pharmacokinetics
++

Absorption: Minimal absorption.

++

Distribution: Action is primarily local.

++

Metabolism and Excretion: <0.9% excreted in urine and feces.

++

Half-life: Unknown.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (regression of lesions)

ROUTE ONSET PEAK DURATION
Topical days–wks 10–16 wk unknown

++
Contraindications/Precautions
++

Contraindicated in: None known.

++

Use Cautiously in: Previous treatment/surgery in affected area (area should be healed prior to use); Preexisting inflammatory skin lesions (may be exacerbated); Immunocompromised patients (safety not established); Pregnancy, lactation, or children <12 yr (safety not established).

++
Interactions
++

Drug-Drug: None known.

++
Route/Dosage
++
External Genital Warts
++

Topical (Adults and children >12 yr): Apply thin layer to warts at bedtime every other day (3 times weekly); leave on for 6–10 hr, then rinse off with mild soap and water. Repeat until lesions are completely cleared or up to 16 wk.

++
Actinic Keratoses
++

Topical (Adults): Apply thin layer to clean, dry affected area twice weekly; leave on for 8 hr, then rinse off with mild soap and water. Continue for 16 wk.

++
Superficial Basal Cell Carcinoma
++

Topical (Adults): Apply thin layer to clean, dry affected area 5 times per ...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.